Temple tragedy: Karnataka sends doctors, plastic surgeons to Kerala

Dubai, Mar 3: Abu Dhabi-based Indian retail tycoon MA Yusuff Ali has become the first Indian to receive Saudi Arabia's premium residency, his office said in a statement on Monday.

Yusuff Ali, 64, is the chairman of the LuLu Group, who was ranked the richest expat in the UAE by the Forbes magazine last year.

The permit, informally known as Saudi Green Card, grants expatriates the right to live, work and own business and property in the Kingdom without need for a sponsor, the LULU group said in a statement.

The introduction of the Premium Residency comes as a part of Saudi Arabia's Vision 2030 reform plan, which was announced by Crown Prince Mohammed bin Salman to boost the Saudi economy, the statement said.

Yusuff Ali said "obviously a very proud and humbling moment in my life. This is a great honour not only for me but for the entire Indian expat community and I sincerely thank the HM the King Salman, HRH Crown Prince Mohamed bin Salman and the government of Saudi Arabia."

"@Yusuffali_MA , an investor from India, after obtaining Premium Residency in Saudi Arabia: ''The Kingdom became an attractive investment destination due to the remarkable growth in economy," Premium Residency tweeted on Monday.

Yusuff Ali said he was sure that this new permanent residency initiative will further boost Saudi Arabia's image as one of the key investments and business hubs of the region as well as attract and retain new investors.

This initiative is targeting key investors and prominent personalities from various fields, including sports, arts & culture, who have played a defining role in the nation building process.

The Lulu Group owns and operates more than 35 hypermarkets and supermarkets in Saudi Arabia, which includes ARAMCO Commissaries and National Guards super stores.

Bengaluru, Mar 11: Did Congress party’s Man Friday, DK Shivakumar, not rise up to the occasion and save the situation for the party, whose rebel MLAs were flown into Bengaluru to unsettle the Kamal Nath-led government in Madhya Pradesh? Shivakumar told The New Indian Express on Tuesday, “So far, I have not got any clear direction on what has to be done. But I am in touch with the central leaders. The party does not want to antagonise them... They are our own MLAs.”

He said that the Tenth Schedule, which makes defections illegal, is very strong. “It is not so easy for them once they are expelled. There are courts and then they have to get re-elected. It is not easy to get minister’s post after getting re-elected,” he added.

When pointed out that rebels from the Congress and JD(S) who joined the BJP have got re-elected and become ministers, he said, “There are other issues here.”

Asked about Digvijay Singh, who is at the centre of the controversy in MP and who was AICC general secretary in-charge of Karnataka, not being able to prevent the rebellion in his home state, Shivakumar said, “I do not want to comment on any of our national leaders.”But he was confident that the Congress government would be saved in MP. “I am aware of the developments and keeping track of them,” he said.

Congress leaders seemed wiser after the event.

One of them, who wished not to be identified, said the party clearly did not see the writing on the wall. “Jyotiraditya Scindia supported the BJP at the Centre when it scrapped Article 370. Later too he was not in line with the Congress position on several issues. But during the recent Delhi violence, he criticised the BJP, sending confusing signals,” he added.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.